Industry Symposia
THURSDAY, APRIL 10
|
12:00-12:30 |
 |
Nexavar: The New Treatment Paradigm in Hepatocellular Carcinoma
Chair: Riccardo Lencioni (Pisa/IT)
New hope for unmet needs in advanced and recurrent hepatocellular carcinoma (HCC)
J. Bruix (Barcelona/ES)
Nexavar as the standard of care in HCC: implications for earlier stages in HCC and future directions
J.M. Llovet (Barcelona/ES)
| 13:00-13:45 Terumo & Biocompatibles |
|
Infarction endpoint in bland embolization and drug eluting beads: latest updates
Chair: A. Denys (Lausanne/CH)
UFE treatment: long-term follow up of bead block registry
T.J. Kröncke (Berlin/DE)
TACE with DC beads as a pretransplant treatment for HCC: results with anatomopathological data
P. Goffette (Brussels/BE)
International hepatic arterial embolization registry of malignant tumours
R. Martin (Lexington, KY/US)
| 13:15 - 14:00 Angiodynamics |
 |
Innovations in embolization and radio frequency ablation
Drug-eluting bead-enhanced RF ablation of liver cancer
R. Lencioni (Pisa/IT)
Latest Optimization Updates of Radio Frequency Ablation lectrodes
L. Appelbaum (Jerusalem/IL)
FRIDAY, APRIL 11
| 12:15-13:00 Bracco |
 |
Contrast enhanced ultrasound in diagnosis and percutaneous treatment procedure -the winning situation
Chairs: R. Lencioni (Pisa/IT), G. Cornalba (Milan/IT)
The role of contrast enhanced ultrasound in HCC patient for diagnosis and during percutaneous treatment
C. Nicolau (Barcelona/ES)
Contrast enhanced ultrasound and fusion imaging: the optimal combination to guide and monitor percutaneous treatment
L. Solbiati (Busto Arsizio/Varese/IT)
Diagnostic performance of CEU’s in the follow-up of cancer patient
S. Yarmenitis (Heraklion/GR)
| 13:00 - 13:45 Boston |
 |
Combined treatment in hepatocellular carcinoma: radiofrequency ablation prior or after TACE?
RFA prior TACE
P. Chevallier (Nice/FR)
RFA after TACE
A. Denys (Lausanne/CH)
Discussion
| 18:15 - 19:00 Covidien |
 |
MWA, a new milestone within ablative therapies
Chair: L. Solbiati (Busto Arsizio/IT)
Basıc Physıcs and Bıophysıcs of Mıcrowave Ablatıon
J. Case (Boulder, CO/US)
Microwave vs. radiofrequency: lessons learned from experimental animal studies
L. Crocetti (Pisa/IT), R. Lencioni (Pisa/IT)
MWA: Overview of Current and Future Clinical Applications in Patients
D. Dupuy (Providence, RI/US)
SATURDAY, APRIL 12
| 10:00-10:45 GE Healthcare |
 |
Chair: D. Gianfelice (Laval/CA)
Changing demographics of cancer in Europe
D.Gianfelice (Laval/CA)
Innovative approaches improve breast cancer outcomes
D.Gianfelice (Laval/CA)
Abdominal cancer. New interventional solutions and applied imaging technologies.
T. de Baère (Villejuif/FR)
| 11:15-11:45 Philips |
 |
Contrast-Enhanced Ultrasound for Interventional Oncology
The role of 3D CEUS in assessing the efficacy of radiofrequency ablation of HCC and the role of quantitative techniques for the evaluation of the efficacy of antitumoral treatments
C. Serra (Bologna/IT)
Back
print page
Top | 08 April 2008 | ||
| Over 1,000 participants from 70 countries registered for the 1st European Conference on Interventional Oncology. The CIRSE Foundation warmly welcomes all delegates. | |||
| 14 January 2008 | ||
| Image-Guided Radiofrequency Tumour Ablation Course Heraklion (GR) July 18-19, 2008 | |||
| 10 December 2007 | ||
| ECIO announces joint session with ILCA (International Liver Cancer Association) | |||
Copyright © CIRSE Foundation (Cardiovascular and Interventional Radiological Society of Europe)